Plasma Donors in the Southwestern United States Positively Contribute to the Diverse Therapeutic Antibody Profile of Immune Globulin Products

[1]  G. Xia,et al.  Hepatitis Awareness Month and Testing Day — May 2019 , 2019, Morbidity and Mortality Weekly Report.

[2]  P. Vandeberg,et al.  Measles antibody trough levels after treatment with immunoglobulin products and predicted levels assuming lower measles antibody specifications , 2018, Transfusion.

[3]  Ivan K. Chinn,et al.  Update on the use of immunoglobulin in human disease: A review of evidence , 2017, The Journal of allergy and clinical immunology.

[4]  M. Costafreda,et al.  Evaluation of Potencies of Immune Globulin Products Against Hepatitis A , 2017, JAMA internal medicine.

[5]  Noele P. Nelson,et al.  Progress Toward Eliminating Hepatitis A Disease in the United States. , 2016, MMWR supplements.

[6]  W. Bellini,et al.  Seroprevalence of Measles, Mumps, Rubella and Varicella Antibodies in the United States Population, 2009–2010 , 2015, Open forum infectious diseases.

[7]  C. Cunningham-Rundles,et al.  An update on the use of immunoglobulin for the treatment of immunodeficiency disorders. , 2014, Immunotherapy.

[8]  W. Bellini,et al.  Measles — United States, January 1–May 23, 2014 , 2014, MMWR. Morbidity and mortality weekly report.

[9]  C. Stenland,et al.  Ensuring the Biologic Safety of Plasma-Derived Therapeutic Proteins , 2012, BioDrugs.

[10]  R. Jacobson,et al.  The re-emergence of measles in developed countries: time to develop the next-generation measles vaccines? , 2012, Vaccine.

[11]  B. Bell,et al.  Seroprevalence of Hepatitis A Virus Antibodies in the U.S.: Results from the National Health and Nutrition Examination Survey , 2011, Public health reports.

[12]  M. Eibl.  History of immunoglobulin replacement. , 2008, Immunology and allergy clinics of North America.

[13]  D. Niebuhr,et al.  Rising hepatitis A immunity in U.S. military recruits. , 2007, Military medicine.

[14]  D. Scott,et al.  Measles-virus-neutralizing antibodies in intravenous immunoglobulins. , 2006, The Journal of infectious diseases.

[15]  Anthony Fiore,et al.  Hepatitis A in the era of vaccination. , 2006, Epidemiologic reviews.

[16]  B. Bell,et al.  Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). , 2006, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[17]  J. Orange,et al.  Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. , 2006, The Journal of allergy and clinical immunology.

[18]  B. Bell,et al.  Incidence of hepatitis A in the United States in the era of vaccination. , 2005, JAMA.

[19]  V. Hemming.  Use of Intravenous Immunoglobulins for Prophylaxis or Treatment of Infectious Diseases , 2001, Clinical Diagnostic Laboratory Immunology.

[20]  T. Doyle,et al.  Infectious disease morbidity in the US region bordering Mexico, 1990-1998. , 2000, The Journal of infectious diseases.

[21]  E. Tabor.  The epidemiology of virus transmission by plasma derivatives: clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1 , 1999, Transfusion.

[22]  H. Rotman,et al.  Hepatitis A antibody titres after infection and immunization: implications for passive and active immunization , 1993, Journal of medical virology.

[23]  R. Snow,et al.  Review of the Evidence. , 1964, Science.

[24]  J. Modrof,et al.  Hepatitis A virus antibodies in immunoglobulin preparations. , 2010, The Journal of allergy and clinical immunology.

[25]  M. Alter,et al.  A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. , 2006, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[26]  Pertussis vaccination: acellular pertussis vaccine for the fourth and fifth doses of the DTP series update to supplementary ACIP statement. Recommendations of the Advisory Committee on Immunization Practices (ACIP). , 1992, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[27]  Ji Jin,et al.  Measles--United States. , 1982, MMWR. Morbidity and mortality weekly report.